GemVax Holds Plaque Unveiling Ceremony for International Progressive Supranuclear Palsy Research and Treatment Center

On October 13, GemVax & KAEL announced that it held a plaque unveiling ceremony for the "International Progressive Supranuclear Palsy Research and Treatment Center" at Bundang Seoul National University Hospital on October 2.

This ceremony marks the fruition of practical collaboration and the establishment of efficient operational plans following the memorandum of understanding signed last year between Bundang Seoul National University Hospital, CurePSP, and GemVax for the creation of an international PSP treatment center.

The event was attended by numerous stakeholders, including Jeon Sanghoon, Honorary Professor at Bundang Seoul National University Hospital and Chair of the Steering Committee for the International Progressive Supranuclear Palsy Research and Treatment Center; Lee Jiyeong, Professor at the Department of Neurology at Seoul National University College of Medicine and Director of the Parkinson's and Rare Disease Center; Kristophe Diaz, CEO of CurePSP; and Lee Seokjun, CEO of GemVax.

The center will establish a foundation encompassing the diagnosis, education, research, and new drug development for PSP and other neurodegenerative diseases.

Bundang Seoul National University Hospital will play a central role in operating the center, as well as in patient care and clinical research. CurePSP, a U.S.-based nonprofit charity, will leverage its expertise and global network built over more than 30 years to enhance international cooperation and provide consultation to the center. GemVax will continue research and development focused on its PSP treatment candidate GV1001, while also supporting the center’s operations.

Song Jeonghan, President of Bundang Seoul National University Hospital, stated, "The International Progressive Supranuclear Palsy Research and Treatment Center has taken its first step as a leader in research and therapeutic development to overcome unmet essential medical needs, such as severe, rare, and intractable diseases." He added, "We will devote our world-class clinical and research capabilities at Bundang Seoul National University Hospital to ensure that patients with rare and intractable diseases are not left in the medical blind spot."

Jeon Sanghoon, Chair of the Steering Committee, commented, "This plaque unveiling ceremony is significant as a new starting point for PSP research and clinical collaboration in Korea. We will strive to provide a better treatment environment for patients and their families and to establish the center as a venue for domestic and international experts to share knowledge and experience."

Professor Lee Jiyeong expressed, "With the launch of the center, we hope to raise the standard of care for patients. We will develop the center into one that brings hope to PSP patients through patient-centered care and research."

Kristophe Diaz, CEO of CurePSP, said, "CurePSP will share its expertise and support the new center to become an influential hub in Korea. We believe that global collaboration is essential to improving treatments and accelerating breakthrough therapies for PSP patients."

CurePSP is a nonprofit charity based in New York, United States, established in 1990. The organization works to raise awareness of neurodegenerative diseases such as PSP, corticobasal degeneration (CBD), and multiple system atrophy (MSA), and provides support and education for patients and families, expands professional networks, and funds research.

A GemVax representative stated, "We hope that the first Progressive Supranuclear Palsy Research and Treatment Center in Korea will become a global hub providing world-class care for patients with rare and intractable diseases both domestically and internationally." The representative added, "With the launch of the center, we hope to see expanded research and development for PSP and other neurodegenerative diseases with significant unmet medical needs, and the company will do its utmost to contribute to meaningful outcomes through new drug development."

On the same day, the "Progressive Supranuclear Palsy Patient Association" was also launched. There are approximately 3,000 patients in Korea. The association serves as a community for PSP patients and their families to share experiences and challenges encountered during treatment and care. It aims to represent patients’ voices and actively promote greater societal awareness and improved treatment environments for the disease.

This content was produced with the assistance of AI translation services.